FDA indications of inhaled NO is
"Inhaled nitric oxide has been approved by FDA for use in newborns with persistent pulmonary hypeension and has become the first line therapy for this disease. In this disease state, NO inhalation has been shown to reduce, significantly, the necessity for extracorporeal oxygenation".(Refer: Morgan and Mikhail's Clinical Anaesthesiology, 5th edition, pg no. 257)
Malignant hypeension
Pulmonary hypeension in newborn
Cyanotic CHD
None of the above
All India exam